Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Robert K. who wrote (14187)	7/20/2000 9:32:34 AM
From: aknahow	Read Replies (1) \| Respond to of 17367

Yes, I see your point and almost agree. In fact I do agree that LLY chose to combine only with BPI in its' application and Merck included two XOMA peptides among many other compounds. To balance the importance however one is an actual patent, and including something very obscure, indeed your original post asked how Merck knew all about these peptides, rather than BPI which is a well know well researched protein, is important. But, certainly it is the LLY aplication that gains the major attention, and is considered by everyone to be the more important of the two.